Next Phase Newsletter

A venture capital firm with offices in Canada was founded by an experienced healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2020 and based in California, the firm is a life science venture capital arm of a large real estate group. The firm is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm  is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in Europe. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. While the firm is open to USA-based opportunities, the firm will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company, headquartered in California, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The company offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks. The company is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest. The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.